哈卡特
药理学
丙酸氯倍他索
医学
碘化丙啶
倍他米松
化学
细胞凋亡
内分泌学
内科学
皮质类固醇
程序性细胞死亡
生物化学
体外
作者
A Guichard,Philippe Humbert,Marion Tissot,Patrice Muret,C. Courderot-Masuyer,Céline Viennet
标识
DOI:10.1016/j.ijpharm.2014.12.066
摘要
Topical-corticosteroids are mainly used for the treatment of inflammatory or hyperproliferative skin diseases. The in vivo assay to rank topical-corticosteroids potency, based on the skin blanching, is not adapted to compare their anti-proliferative efficacy. We have compared the antiproliferative effect of six topical-corticosteroids on a model of hyperproliferant keratinocytes (HaCaT). Betamethasone-dipropionate; clobetasol-propionate; betamethasone-valerate; desonide; hydrocortisone-butyrate and hydrocortisone-base, at different concentrations (10−8–10−4 M) have been compared. HaCaT proliferation has been evaluated by MTT-assay and the mechanism of the death was evaluated by annexin V/propidium iodide staining and cell cycle phases analysis. Topical corticosteroids reduced cell growth in a dose-dependent manner. At 10−4 M, betamethasone dipropionate was the most antiproliferative compound while hydrocortisone-butyrate was the less. Hydrocortisone-base which is usually considered as the less potent topical-corticosteroids showed a clear cytotoxic effect. Betamethasone-dipropionate and betamethasone-valerate induced more apoptosis than necrosis whereas the reverse has been observed for other topical-corticosteroids. All topical-corticosteroids, except clobetasol-propionate, arrested cell cycle mainly in G2-phase. Clobetasol-propionate arrested cell cycle in S-phase population. At 10−8 M, topical-corticosteroids induced HaCaT proliferation. In terms of antiproliferative effect at 10−4 M, we propose to rank topical corticosteroids as follow: betamethasone-dipropionate > desonide ≥ betamethasone-valerate = hydrocortisone-base = clobetasol-propionate > hydrocortisone-butyrate. This classification differs from the current ranking, based on the vasoconstrictive effect, but is more adapted for hyperproliferative disease treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI